Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

April 4, 2016

Primary Completion Date

June 26, 2017

Study Completion Date

September 13, 2017

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

SOF/VEL

400/100 mg FDC tablet administered orally once daily

Trial Locations (15)

Unknown

Krasnoyarsk Regional Center of AIDS Prevention, Krasnoyarsk

Central Research Institute of Epidemiology, Moscow

Central Scientific-Research Institute of Epidemiology, Moscow

City Clinical Hospital # 24, Moscow

First Moscow Medical University I.M.Sechenov., Moscow

First Moscow State Medical University I.M. Sechenov, Moscow

"Limited Liability Company Clinic Tour", Moscow

Scientific Research Institute of Nutrition, Moscow

Sklifosovsky Scientific Research Institution of Emergency Care, Moscow

Center for Prevention and Control of AIDS and Infectious Diseases, Saint Petersburg

Kirov Medical Military Academy, Saint Petersburg

North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg

"LLC Medical Company Hepatolog", Samara

Sahlgrenska Universitetsjukhuset, Gothenburg

Karolinska University Hospital Huddinge, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY